argenx(ARGX) - 2020 Q3 - Earnings Call Presentation

Efgartigimod (IV/SC) Clinical Trial Results & Regulatory Progress - In AChR-Ab+ patients, 84.1% of MG-ADL responders (37/44) had onset of effect in the first two weeks[10] - 40% of Efgartigimod patients achieved minimal symptom expression compared to 11% in placebo[13] - Across cycles 1 and 2, 78.5% (51/65) of efgartigimod patients were MG-ADL responders[22] - 36.8% (7/19) of efgartigimod patients who were not MG-ADL responders in cycle 1 and were retreated achieved MG-ADL responder for the first time in cycle 2[24] - In the overall population, 67.9% of efgartigimod patients were MG-ADL responders compared to 37.3% of placebo patients[26] - BLA filing for IV Efgartigimod is expected by the end of 2020, and J-MAA filing expected in 1H21[29, 55] Pipeline Development - Phase 3 trial for SC Efgartigimod in PV is planned to start in 4Q20[29] - Topline data for Cusatuzumab + AZA in newly diagnosed AML (unfit) is expected in early 2021[29, 39] Financial Results - The company's cash, cash equivalents, and current financial assets at the end of the period were €1,804,043 thousand[58] - The net loss for the period was €363,296 thousand[58]